143 related articles for article (PubMed ID: 15459209)
1. Is baseline quality of life useful for predicting survival with hormone-refractory prostate cancer? A pooled analysis of three studies of the European Organisation for Research and Treatment of Cancer Genitourinary Group.
Collette L; van Andel G; Bottomley A; Oosterhof GO; Albrecht W; de Reijke TM; Fossà SD
J Clin Oncol; 2004 Oct; 22(19):3877-85. PubMed ID: 15459209
[TBL] [Abstract][Full Text] [Related]
2. Validation of patient's self-reported social functioning as an independent prognostic factor for survival in metastatic colorectal cancer patients: results of an international study by the Chronotherapy Group of the European Organisation for Research and Treatment of Cancer.
Efficace F; Innominato PF; Bjarnason G; Coens C; Humblet Y; Tumolo S; Genet D; Tampellini M; Bottomley A; Garufi C; Focan C; Giacchetti S; Lévi F;
J Clin Oncol; 2008 Apr; 26(12):2020-6. PubMed ID: 18421055
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of health-related quality-of-life data in predicting survival in patients with anaplastic oligodendrogliomas, from a phase III EORTC brain cancer group study.
Mauer ME; Taphoorn MJ; Bottomley A; Coens C; Efficace F; Sanson M; Brandes AA; van der Rijt CC; Bernsen HJ; Frénay M; Tijssen CC; Lacombe D; van den Bent MJ;
J Clin Oncol; 2007 Dec; 25(36):5731-7. PubMed ID: 18089867
[TBL] [Abstract][Full Text] [Related]
4. Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer.
Efficace F; Biganzoli L; Piccart M; Coens C; Van Steen K; Cufer T; Coleman RE; Calvert HA; Gamucci T; Twelves C; Fargeot P; Bottomley A;
Eur J Cancer; 2004 May; 40(7):1021-30. PubMed ID: 15093577
[TBL] [Abstract][Full Text] [Related]
5. Health-related quality of life as a survival predictor for patients with localized head and neck cancer treated with radiation therapy.
Meyer F; Fortin A; Gélinas M; Nabid A; Brochet F; Têtu B; Bairati I
J Clin Oncol; 2009 Jun; 27(18):2970-6. PubMed ID: 19451440
[TBL] [Abstract][Full Text] [Related]
6. Quality of life in patients with skeletal metastases of prostate cancer and status prior to start of endocrine therapy: results from the Scandinavian Prostate Cancer Group Study 5.
Jønler M; Nielsen OS; Groenvold M; Hedlund PO; Damber L; Hedelin H; Waldén M;
Scand J Urol Nephrol; 2005; 39(1):42-8. PubMed ID: 15764270
[TBL] [Abstract][Full Text] [Related]
7. Analysis of biochemical bone markers as prognostic factors for survival in patients with hormone-resistant prostate cancer and bone metastases.
Petrioli R; Rossi S; Caniggia M; Pozzessere D; Messinese S; Sabatino M; Marsili S; Correale P; Salvestrini F; Manganelli A; Francini G
Urology; 2004 Feb; 63(2):321-6. PubMed ID: 14972482
[TBL] [Abstract][Full Text] [Related]
8. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
[TBL] [Abstract][Full Text] [Related]
9. The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480.
George DJ; Halabi S; Shepard TF; Sanford B; Vogelzang NJ; Small EJ; Kantoff PW
Clin Cancer Res; 2005 Mar; 11(5):1815-20. PubMed ID: 15756004
[TBL] [Abstract][Full Text] [Related]
10. Does a patient's self-reported health-related quality of life predict survival beyond key biomedical data in advanced colorectal cancer?
Efficace F; Bottomley A; Coens C; Van Steen K; Conroy T; Schöffski P; Schmoll H; Van Cutsem E; Köhne CH
Eur J Cancer; 2006 Jan; 42(1):42-9. PubMed ID: 16298522
[TBL] [Abstract][Full Text] [Related]
11. Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma.
Bottomley A; Coens C; Efficace F; Gaafar R; Manegold C; Burgers S; Vincent M; Legrand C; van Meerbeeck JP;
J Clin Oncol; 2007 Dec; 25(36):5770-6. PubMed ID: 18089874
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen response duration and risk of death for patients with hormone-refractory metastatic prostate cancer.
D'Amico AV; Chen MH; Cox MC; Dahut W; Figg WD
Urology; 2005 Sep; 66(3):571-6. PubMed ID: 16140080
[TBL] [Abstract][Full Text] [Related]
13. New standards in the chemotherapy of metastatic hormone-refractory prostate cancer.
Sava T; Basso U; Porcaro A; Cetto GL
Expert Rev Anticancer Ther; 2005 Feb; 5(1):53-62. PubMed ID: 15757438
[TBL] [Abstract][Full Text] [Related]
14. Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study.
Bottomley A; Gaafar R; Manegold C; Burgers S; Coens C; Legrand C; Vincent M; Giaccone G; Van Meerbeeck J; ;
J Clin Oncol; 2006 Mar; 24(9):1435-42. PubMed ID: 16446322
[TBL] [Abstract][Full Text] [Related]
15. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).
Hussain M; Tangen CM; Higano C; Schelhammer PF; Faulkner J; Crawford ED; Wilding G; Akdas A; Small EJ; Donnelly B; MacVicar G; Raghavan D;
J Clin Oncol; 2006 Aug; 24(24):3984-90. PubMed ID: 16921051
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
James ND; Caty A; Borre M; Zonnenberg BA; Beuzeboc P; Morris T; Phung D; Dawson NA
Eur Urol; 2009 May; 55(5):1112-23. PubMed ID: 19042080
[TBL] [Abstract][Full Text] [Related]
17. PSA kinetics provide improved prediction of survival in metastatic hormone-refractory prostate cancer.
Robinson D; Sandblom G; Johansson R; Garmo H; Aus G; Hedlund PO; Varenhorst E;
Urology; 2008 Oct; 72(4):903-7. PubMed ID: 18639324
[TBL] [Abstract][Full Text] [Related]
18. Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials.
Quinten C; Coens C; Mauer M; Comte S; Sprangers MA; Cleeland C; Osoba D; Bjordal K; Bottomley A;
Lancet Oncol; 2009 Sep; 10(9):865-71. PubMed ID: 19695956
[TBL] [Abstract][Full Text] [Related]
19. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111.
Hussain M; Tangen CM; Lara PN; Vaishampayan UN; Petrylak DP; Colevas AD; Sakr WA; Crawford ED;
J Clin Oncol; 2005 Dec; 23(34):8724-9. PubMed ID: 16314632
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study.
Taplin ME; George DJ; Halabi S; Sanford B; Febbo PG; Hennessy KT; Mihos CG; Vogelzang NJ; Small EJ; Kantoff PW
Urology; 2005 Aug; 66(2):386-91. PubMed ID: 16098367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
